Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 11, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
March 28, 2023 07:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features

Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the Montgomery Asberg Depression Rating Scale (MADRS) for each patient population including: -combined...
March 01, 2023 07:30 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Full year 2022 total revenues of $250.3 million, compared to $83.8 million in 2021 CAPLYTA fourth quarter 2022 net product sales grew to $87.4 million, a 243% increase over the same period in 2021...
February 14, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
February 08, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference

NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
January 03, 2023 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
December 08, 2022 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting

NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
November 10, 2022 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
November 03, 2022 07:30 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

CAPLYTA net product revenues for the third quarter 2022 were $71.9 million, compared to $21.6 million for the same period in 2021, representing a 233% increase over the same period in 2021 and a 30%...
October 27, 2022 08:00 ET | Source: Intra-Cellular Therapies Inc.

Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...